At just two years old, immunology startup GentiBio has signed a collaboration deal with a major pharmaceutical company that could be worth up to $1.9 billion.
Bristol Myers Squibb Co. has partnered with the Boston biotech company to work on three programs in inflammatory bowel disease, or IBD. The goal is to use GentiBio’s specially engineered regulatory T-cells, or T-regs, to re-establish immune tolerance and repair tissue in patients with IBD, which affects at least 3 million American adults.
Bristol Myers Squibb is a 2022 Tax Incentive awardee. This program provides incentives to companies, of all sizes, looking to expand their efforts by creating new, long-term jobs in Massachusetts.
